CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 17, 2014--
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage
biopharmaceutical company developing nucleotide therapeutics for
patients with cancer and orphan diseases, today announced that Sudhir
Agrawal, D. Phil., Chief Executive Officer, will participate in a panel
discussion entitled “RNA/DNA: Getting It Where You Need It” at
the Piper Jaffray GenomeRx Symposium on Monday, June 23, 2014. The panel
is scheduled to begin at 3:30 p.m. EDT and will take place in New York
City.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals is a
clinical-stage biopharmaceutical company developing a novel therapeutic
approach for the treatment of genetically defined forms of B-cell
lymphoma and orphan autoimmune diseases. Idera’s proprietary technology
involves creating novel nucleic acid therapeutics designed to inhibit
over-activation of Toll-like Receptors (TLRs). In addition to its TLR
programs, Idera is developing gene silencing oligonucleotides (GSOs)
that it has created using its proprietary technology to inhibit the
production of disease-associated proteins by targeting RNA.
Source: Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Sarah Carmody, 617-679-5552
scarmody@iderapharma.com
